apomorphine has been researched along with selegiline in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (26.92) | 18.7374 |
| 1990's | 9 (34.62) | 18.2507 |
| 2000's | 7 (26.92) | 29.6817 |
| 2010's | 3 (11.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Rinne, UK | 1 |
| Levivier, M; Przedborski, S | 1 |
| Quinn, N | 1 |
| Bhattacharya, SK; Datla, KP | 1 |
| Chambers, KC; Phoenix, CH | 1 |
| Knoll, B; Knoll, J; Timar, J | 1 |
| Hietala, J; Koulu, M; Scheinin, M; Syvälahti, E | 1 |
| Koulu, M; Lammintausta, R | 2 |
| Agnoli, A; Baldassarre, M; D'Urso, R; Del Roscio, S; Falaschi, P; Frajese, G; Mearelli, S; Rocco, A; Ruggieri, S | 1 |
| Hastie, IR; Mukherjee, D | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 1 |
| Araya, F; Castillo, JL; Miranda, CM; Sáez, D | 1 |
| Oertel, WH; Quinn, NP | 1 |
| Gentsch, C; Spooren, WP; Waldmeier, P | 1 |
| Chesnut, MD; Dwoskin, LP; Geddes, JW; Jakel, RJ; Maragos, WF | 1 |
| Sternon, J; Supiot, F; Zegers de Beyl, D | 1 |
| Chen, RC; Chen, TH; Liou, HH; Tsai, MC; Tsai, YF | 1 |
| Baillet, C; Callizot, N; Guénet, JL; Poindron, P; Warter, JM | 1 |
| Hayashi, K; Knoll, J; Sato, N; Shimazu, S; Tanigawa, A; Yoneda, F | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Caramelli, A; Corsini, GU; Pardini, C; Vaglini, F; Viaggi, C | 1 |
| de Oliveira, EF; de Rezende, IC; Fernandes, A; Ponzoni, S | 1 |
7 review(s) available for apomorphine and selegiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent advances in research on Parkinsonism.
Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarboxylase; Dopamine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Selegiline; Serotonin; Substance P; Tyrosine 3-Monooxygenase | 1978 |
[Current therapeutic approach in Parkinson disease].
Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Fetal Tissue Transplantation; Humans; Levodopa; Mesencephalon; Parkinson Disease; Selegiline; Vitamin E | 1992 |
The modern management of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Humans; Levodopa; Parkinson Disease; Selegiline | 1990 |
New directions in the drug treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1996 |
Parkinson's disease: drug therapy.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Dyskinesia, Drug-Induced; Guidelines as Topic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome | 1997 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
19 other study(ies) available for apomorphine and selegiline
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Effect of selective monoamine oxidase A and B inhibitors on footshock induced aggression in paired rats.
Topics: Aggression; Animals; Apomorphine; Clorgyline; Female; Male; Monoamine Oxidase; Nialamide; Pain; Rats; Rats, Inbred Strains; Selegiline | 1990 |
Apomorphine, deprenyl, and yohimbine fail to increase sexual behavior in rhesus males.
Topics: Age Factors; Animals; Apomorphine; Arousal; Brain; Copulation; Dose-Response Relationship, Drug; Ejaculation; Female; Macaca mulatta; Male; Phenethylamines; Receptors, Adrenergic; Receptors, Dopamine; Selegiline; Sexual Behavior, Animal; Yohimbine | 1989 |
Long-term administration of (-)deprenyl (selegiline), a compound which facilitates dopaminergic tone in the brain, leaves the sensitivity of dopamine receptors to apomorphine unchanged.
Topics: Animals; Apomorphine; Clorgyline; Dextroamphetamine; Drug Interactions; Female; Haloperidol; Imipramine; Male; Phenethylamines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Selegiline; Stereotyped Behavior | 1986 |
Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
Topics: Apomorphine; Bromocriptine; Growth Hormone; Homovanillic Acid; Humans; Levodopa; Male; Metoclopramide; Monitoring, Physiologic; Neurosecretory Systems; Prolactin; Receptors, Dopamine; Schizophrenia; Selegiline; Time Factors | 1985 |
Human growth hormone and dopaminergic drugs, with special reference to deprenyl (selegiline): a summary of studies on volunteers.
Topics: Apomorphine; Bromocriptine; Dopamine; gamma-Aminobutyric Acid; Growth Hormone; Humans; Levodopa; Phenethylamines; Receptors, Dopamine; Selegiline; Synapses | 1983 |
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Prolactin; Receptors, Dopamine; Selegiline; Tremor | 1980 |
Effects of L-deprenyl on human growth hormone secretion.
Topics: Adult; Apomorphine; Growth Hormone; Humans; Kinetics; Levodopa; Male; Phenethylamines; Selegiline; Tryptophan | 1981 |
Parkinson's disease.
Topics: Apomorphine; Brain; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1995 |
[Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Electric Stimulation; Evoked Potentials, Somatosensory; Female; Frontal Lobe; Humans; Levodopa; Male; Median Nerve; Middle Aged; Motor Skills; Parietal Lobe; Parkinson Disease; Reaction Time; Selegiline; Walking | 1996 |
The effect of a subchronic post-lesion treatment with (-)-deprenyl on the sensitivity of 6-OHDA-lesioned rats to apomorphine and d-amphetamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Agents; Homovanillic Acid; Male; Medial Forebrain Bundle; Oxidopamine; Rats; Rats, Sprague-Dawley; Selegiline | 1999 |
Does dopamine contribute to striatal damage caused by impaired mitochondrial function?
Topics: Animals; Apomorphine; Biological Transport; Clorgyline; Corpus Striatum; Dopamine; Malonates; Medial Forebrain Bundle; Mitochondria; Monoamine Oxidase Inhibitors; Nitro Compounds; Oxidopamine; Propionates; Rats; Selegiline; Substantia Nigra | 1999 |
[Dopaminergic agonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles | 2000 |
Attenuation of paraquat-induced dopaminergic toxicity on the substantia nigra by (-)-deprenyl in vivo.
Topics: Animals; Apomorphine; Behavior, Animal; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Herbicides; Male; Neuroprotective Agents; Paraquat; Rats; Rats, Wistar; Selegiline; Stereotyped Behavior; Substantia Nigra | 2001 |
The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Electromyography; Female; Genes, Recessive; Immunohistochemistry; Indoles; Levodopa; Male; Memory Disorders; Mice; Mice, Inbred C3H; Mice, Neurologic Mutants; Motor Activity; Neurons; Parkinson Disease, Secondary; Postural Balance; Selegiline; Tyrosine 3-Monooxygenase | 2001 |
Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes.
Topics: Animals; Apomorphine; Astrocytes; Benzofurans; Brain-Derived Neurotrophic Factor; Cells, Cultured; Dose-Response Relationship, Drug; Glial Cell Line-Derived Neurotrophic Factor; Mice; Mice, Inbred ICR; Nerve Growth Factors; Neuroprotective Agents; Selegiline | 2003 |
Apomorphine offers new insight into dopaminergic neuron vulnerability in mesencephalic cultures.
Topics: Animals; Apomorphine; Cell Survival; Cells, Cultured; Choline; Dopamine; Dopamine Agonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Embryo, Mammalian; Female; L-Lactate Dehydrogenase; Mazindol; Mesencephalon; Mice; Monoamine Oxidase Inhibitors; Neurons; Pregnancy; Selegiline; Tyrosine 3-Monooxygenase | 2008 |
Manganese neurotoxic time course is not influenced by L-deprenyl systemic treatment: influence of L-deprenyl in manganese neurotoxic time course.
Topics: Animals; Apomorphine; Corpus Striatum; Dopamine Agonists; Immunohistochemistry; Male; Manganese; Monoamine Oxidase Inhibitors; Motor Activity; Neuroprotective Agents; Photomicrography; Rats; Rotation; Selegiline; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2010 |